Preview complete
The prescreener preview is complete. You may now close the preview.
AI-powered
PrecISE: Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network
Study on Investigational Treatments for Severe Asthma
Recruiting
12 years - 80 years
All
Phase
2
1 Location
Brief description of study.
PrecISE is a multi-site study, sponsored by the National Heart, Lung, and Blood Institute. We are inviting people to participate in PrecISE who: 1) are age 12 or older, 2) meet guideline criteria for severe asthma, 3) currently have uncontrolled asthma, or continue to have exacerbations (attacks), and 4) are on a stable regimen of asthma medications (controller/daily medication). We will find out if you qualify for the study after you finish the screening tests.
Detailed description of study
This study is designed to investigate new treatments for asthma that are thought to work better in some patients than in others. The data from this research study will be used to determine which treatments work and what kind of patient benefits the most from that treatment.
If you choose to take part in the study, you can receive several different treatments depending on when you begin the study. You will take each treatment for about 4 months, and then take a break for 2 to 4 months, before starting another treatment. The study will run for about 3 ½ years, and most of the people participating in the study will go through 2-3 different treatments before finishing the study.
If you choose to take part in the study, you can receive several different treatments depending on when you begin the study. You will take each treatment for about 4 months, and then take a break for 2 to 4 months, before starting another treatment. The study will run for about 3 ½ years, and most of the people participating in the study will go through 2-3 different treatments before finishing the study.
PrecISE is a network of leading universities, medical doctors, and scientists dedicated to helping people living with severe asthma. The two goals of PrecISE are to (1) evaluate exciting new treatments for severe asthma and (2) find patient subgroups for which these treatments work the best.
The main study website is: https://preciseasthma.org
Indiana Site Information:
PI: James F. Chmiel, MD
Research Team: Lisa France, RN and Sylvia Jara, RN
Email: IUasthma@iupui.edu
Phone: 317-274-3380
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: child,children,ped,pediatric,adult,asthma
-
Age: 12 years - 80 years
-
Gender: All
You may be eligible to join if you:
• Are age 12 and up.
• Have severe asthma as defined by commonly accepted guidelines.
• Currently have uncontrolled asthma, or worsening asthma & attacks.
• Are on a stable regimen of asthma medications.
• Are not pregnant and not breastfeeding.
• Are not taking part in other clinical trials.
• Have access to a smartphone or tablet for use during the study.
This study investigates treatments for severe asthma, a condition where airways in the lungs are inflamed and narrow, making it difficult to breathe. This study aims to explore which treatments work best for different patients with severe asthma.
Participants will receive several treatments, each lasting about four months, with breaks in between. The study will not use actual medicine in some cases, known as a placebo, which looks like the real treatment but does not contain active medicine.
- Who can participate: Individuals aged 12 and older with severe, uncontrolled asthma who are stable on their asthma medications may be eligible. Participants should not be pregnant or breastfeeding and must not be in other clinical trials.
- Study details: Participants will receive various treatments for severe asthma, with each treatment lasting around four months. A placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine, may be used in the study.
- Study Timelines: The study will last 3 ½ years.
Updated on
19 Feb 2024.
Study ID: 1909045607
Pre-Screener
